Iovance’s Amtagvi sees ‘healthy demand’ after US approval
Around 12 days after winning an FDA thumbs up, Iovance Biotherapeutics’ advanced melanoma treatment Amtagvi has signed on 20 patients in what analysts describe as a promising launch.
The tumor-infiltrating lymphocyte (TIL) therapy was the first of its kind to win US accelerated approval on Feb. 16. It is also the first FDA-approved T cell therapy for a solid tumor indication, specifically in advanced melanoma that persists after treatment with an anti-PD-1 and targeted therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
